UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells

PloS one, 2013-05, Vol.8 (5), p.e64138-e64138

2013

Volltextzugriff (PDF)

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials

PloS one, 2013-03, Vol.8 (3), p.e57838-e57838

2013

Volltextzugriff (PDF)

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo

The Journal of clinical investigation, 2016-06, Vol.126 (6), p.2341-2355

2016

Volltextzugriff (PDF)

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

Blood, 2010-08, Vol.116 (7), p.1035-1044

2010

Volltextzugriff (PDF)

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo

The Journal of clinical investigation, 2016-06, Vol.126 (6), p.2341-2355

2016

Volltextzugriff (PDF)

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies

Human gene therapy, 2012-05, Vol.23 (5), p.444-450

2012

Volltextzugriff (PDF)

Mitochondrial Biomass As a Measure of Fitness for T Cells Expressing Chimeric Antigen Receptors

Blood, 2015-12, Vol.126 (23), p.3242-3242

2015

Volltextzugriff (PDF)

CD62L+ NKT cells have superior in vivo persistence and anti-tumor activity

The Journal of immunology (1950), 2016-05, Vol.196 (1_Supplement), p.142-142.1

2016

Volltextzugriff (PDF)

Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity

Journal of immunotherapy (1997), 2014-05, Vol.37 (4), p.204-213

2014

Volltextzugriff (PDF)

410. The Development of HLAnull K562 Cells Expressing CD1d and Co-Stimulatory Molecules as Artificial Antigen-Presenting Cells for Clinical Scale Expansion of NKT Cells With Superior In Vivo Persistence and Anti-Tumor Potential

Molecular therapy, 2015-05, Vol.23, p.S162-S162

2015

Volltextzugriff (PDF)

The development of genetically modified K562 cells as artificial antigen presenting cells for NKT cells (P4310)

The Journal of immunology (1950), 2013-05, Vol.190 (1_Supplement), p.45-45.3

2013

Volltextzugriff (PDF)

NKT cells have prolonged persistence and antitumor activity in vivo

The Journal of clinical investigation, 2016-06, p.2341

2016

Volltextzugriff (PDF)

CD62L super( +) NKT cells have prolonged persistence and antitumor activity in vivo

The Journal of clinical investigation, 2016-06, Vol.126 (6), p.2341-2341

2016

Volltextzugriff (PDF)

CD62L^sup +^ NKT cells have prolonged persistence and antitumor activity in vivo

The Journal of clinical investigation, 2016-06, Vol.126 (6), p.2341

2016

Volltextzugriff (PDF)

Good T cells for bad B cells

Blood, 2012-03, Vol.119 (12), p.2700-2702

2012

Volltextzugriff (PDF)

Specifically Targeting the Interface Between HER1-HER3 Heterodimer on Breast Cancer to Limit Off-Target Effects Using Chimeric Antigen Receptor Designs with Improved T-Cell Energy Balance

Blood, 2014-12, Vol.124 (21), p.2151-2151

2014

Volltextzugriff (PDF)

Chimeric Antigen Receptor

PloS one, 2013-03, Vol.8 (3), p.e57838

2013

Volltextzugriff (PDF)

Abstract A179: Ex vivo generation of clinical grade T cells by using activating and propagating feeder cells to cross-link T cell receptor

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.A179-A179

2016

Volltextzugriff (PDF)

Driving CAR-Based T-Cell Therapy to Success

Current hematologic malignancy reports, 2014-03, Vol.9 (1), p.50-56

2014

Volltextzugriff (PDF)

Induction, purification and partial characterization of vitellogenin in an Indian major carp Catla catla (Ham.)

Aquaculture research, 2013-11, Vol.44 (12), p.1901-1911

2013

Volltextzugriff (PDF)

Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor

Blood, 2013-11, Vol.122 (21), p.4208-4208

2013

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies

Mitochondrial Biomass As a Measure of Fitness for T Cells Expressing Chimeric Antigen Receptors

CD62L+ NKT cells have superior in vivo persistence and anti-tumor activity

Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity

410. The Development of HLAnull K562 Cells Expressing CD1d and Co-Stimulatory Molecules as Artificial Antigen-Presenting Cells for Clinical Scale Expansion of NKT Cells With Superior In Vivo Persistence and Anti-Tumor Potential

The development of genetically modified K562 cells as artificial antigen presenting cells for NKT cells (P4310)

NKT cells have prolonged persistence and antitumor activity in vivo

CD62L super( +) NKT cells have prolonged persistence and antitumor activity in vivo

CD62L^sup +^ NKT cells have prolonged persistence and antitumor activity in vivo

Good T cells for bad B cells

Specifically Targeting the Interface Between HER1-HER3 Heterodimer on Breast Cancer to Limit Off-Target Effects Using Chimeric Antigen Receptor Designs with Improved T-Cell Energy Balance

Chimeric Antigen Receptor

Abstract A179: Ex vivo generation of clinical grade T cells by using activating and propagating feeder cells to cross-link T cell receptor

Driving CAR-Based T-Cell Therapy to Success

Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies

Induction, purification and partial characterization of vitellogenin in an Indian major carp Catla catla (Ham.)

Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor

Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor

Suchergebnisse filtern